Immunofluorescence analysis of DNA damage response protein p53-binding protein 1 in a case of uterine dedifferentiated leiomyosarcoma arising from leiomyoma

Matsuda, Katsuya; Akazawa, Yuko; Yamaguchi, Yuka; Mussazhanova, Zhanna; Kurohama, Hirokazu; Ueki, Nobue; Kohno, Michiharu; Fukushima, Ayako; Kajimura, Itsuki; Hiraki, Hiroko; Matsuwaki, Takahiro; Kawashita, Sayaka; Kinoshita, Akira; Nakashima, Masahiro

doi:10.1016/j.prp.2019.152640

Cited by 6 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Review of the literature identified 11 primary dedifferentiated uterine LMS 12,16–21 . Follow‐up was available in six cases, of whom three had died of disease at 4, 6, and 17 months, 16,17 one had died of other causes at 12 months, 12 and two were alive without disease at 12 and 28 months 12,19 .…”

Section: Discussionmentioning

confidence: 99%

“…Review of the literature identified 11 primary dedifferentiated uterine LMS. 12,[16][17][18][19][20][21] Follow-up was available in six cases, of whom three had died of disease at 4, 6, and 17 months, 16,17 one had died of other causes at 12 months, 12 and two were alive without disease at 12 and 28 months. 12,19 The literature also contains eight additional cases of primary conventional uterine LMS with subsequent dedifferentiation at metastatic sites, 16,21 with death from disease at median 7 months (range 1-18 months) after dedifferentiation.…”

Section: Discussionmentioning

confidence: 99%

“…[12][13][14][15] In contrast, reports of dedifferentiated uterine LMS are limited. 12,[16][17][18][19][20][21] We hypothesised that dedifferentiation in uterine LMS is likely underrecognised, and that, when present, it heralds particularly aggressive behaviour, warranting prospective recognition.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dedifferentiated leiomyosarcoma of the uterus: a clinicopathologic and immunohistochemical analysis of 23 cases

et al. 2023

View full text Add to dashboard Cite

Dedifferentiated leiomyosarcoma of the uterus: a clinicopathologic and immunohistochemical analysis of 23 casesAims: To morphologically and immunophenotypically characterize dedifferentiated uterine leiomyosarcoma (LMS). Methods and results: We identified 23 dedifferentiated uterine LMS, defined as a malignant uterine smooth muscle tumour containing discrete differentiated and dedifferentiated components (i.e. with and without morphologic and immunophenotypic evidence of smooth muscle differentiation, respectively). The differentiated component was leiomyosarcoma in most cases (17/23), though some arose from a leiomyoma (n = 4) or smooth muscle tumour of uncertain malignant potential (n = 2). The dedifferentiated tumour component showed noncohesive polygonal cells with moderate to abundant cytoplasm, pleomorphic nuclei with coarse vesicular to smudged chromatin, one or more macronucleoli, frequent multinucleation, and atypical mitoses. Three cases showed heterologous osteosarcomatous or chondrosarcomatous differentiation. Immunohistochemistry revealed alterations characteristic of uterine LMS, including Rb loss (18/19); strong diffuse p16 (17/19); strong diffuse (9/19) or complete absence of (5/19) p53; and ATRX loss (6/16). Compared to a control cohort of uterine LMS without dedifferentiation, dedifferentiated uterine LMS showed significantly shorter disease-specific (median, 54 versus 20 months; 5-year DSS, 46% versus 36%; P = 0.04) and disease-free (median, 31 versus 8 months; 5-year DFS, 42% versus 8%; P = 0.002) survival. Of 19 dedifferentiated uterine LMS with follow-up, 12 had died of disease at median 14 (range, 2-73) months; four were alive with disease at 4, 12, 44, and 50 months; and three were alive with no evidence of disease at 56, 109, and 114 months. Conclusion: Routine prospective recognition of dedifferentiated uterine LMS and distinction from mimics is advocated for accurate prognostication and for further characterisation of these tumours.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dedifferentiated leiomyosarcoma of the uterus: a clinicopathologic and immunohistochemical analysis of 23 cases

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Instead, both large focus and diffuse types are significantly associated with high-grade urothelial carcinoma showing chromosomal instability and poor prognosis ( 10 ). Moreover, in a rare case of uterine dedifferentiated leiomyosarcoma arising from leiomyoma, we observed that the diffuse 53BP1 expression was restricted only to the sarcoma component, and frequently co-localized with p53 overexpression in sarcoma cells, including highly atypical multinucleated giant cells, suggesting aneuploidy ( 14 ). Thus, our analyses revealed that although there is variation in 53BP1 expression among divergent tumors, the high DDR, large focus, and diffuse types of 53BP1 expression were closely associated with high-grade malignancy.…”

Section: Discussionmentioning

confidence: 91%

“…The frequency of low DDR type significantly decreased, while that of abnormal type significantly increased in the Figure 2). Moreover, in a rare case of uterine dedifferentiated leiomyosarcoma arising from leiomyoma, we observed that the diffuse 53BP1 expression was restricted only to the sarcoma component, and frequently co-localized with p53 overexpression in sarcoma cells, including highly atypical multinucleated giant cells, suggesting aneuploidy (14).…”

Section: Abnormal Types Of 53bp1 Expression As An Indicator To Detect Fcmentioning

confidence: 83%

53BP1 expression as a biomarker to differentiate thyroid follicular tumors

Sato

Matsuda

Motoyama

et al. 2021

Endocrine Connections

Self Cite

View full text Add to dashboard Cite

We have previously reported that the expression of p53-binding protein 1 (53BP1) in nuclear foci (NF), a marker reflecting DNA damage response (DDR), detected using immunofluorescence (IF) is useful to estimate the malignant potency of diverse cancers. In this prospective study, we clarified the impact of 53BP1 expression via IF as a biomarker to differentiate thyroid follicular tumors (FTs) with liquid-based cytology (LBC). A total of 183 consecutively obtained-LBC samples, which were preoperatively suspected as FTs, were analyzed. Before histological diagnosis, the type of 53BP1 immunoreactivity in LBC was classified as follows: low DDR type, one or two NF; high DDR type, three or more NF; large foci type, larger than 1.0 μm; abnormal type, intense nuclear staining. Among the 183 cases, 136 cases were postoperatively diagnosed as FTs including adenomatous goiter (AG, n=30), follicular adenoma (FA, n=60), FT-uncertain malignant potency (FT-UMP, n=18), and follicular carcinoma (FC, n=28), and 47 cases were diagnosed as tumors other than FTs or technically inadequate materials. Total 136 FT cases were collated with the type of 53BP1 immunoreactivity in LBC. The mean incidence expressing abnormal 53BP1 expression was significantly higher in FC than FA (9.5% vs. 2.6%, p-value <0.001). When adopting 4.3% as a cut-off value to distinguish FC from FA, the sensitivity, specificity, positive predictive value, and negative predictive value were 89.3, 83.3, 71.4, and 94.3%, respectively. Therefore, IF analysis of 53BP1 expression can be employed as a novel technique to diagnosis FTs and distinguish between different types of FTs using LBC.

show abstract

Glutathione - IR 797 coupled Casein Nano-Trojan for augmenting the therapeutic efficacy of camptothecin in highly invasive triple negative breast cancer

Khatun,

Pebam,

Sankaranarayanan

et al. 2024

Biomaterials Advances

View full text Add to dashboard Cite

Immunofluorescence analysis of DNA damage response protein p53-binding protein 1 in a case of uterine dedifferentiated leiomyosarcoma arising from leiomyoma

Cited by 6 publications

References 23 publications

Dedifferentiated leiomyosarcoma of the uterus: a clinicopathologic and immunohistochemical analysis of 23 cases

Dedifferentiated leiomyosarcoma of the uterus: a clinicopathologic and immunohistochemical analysis of 23 cases

53BP1 expression as a biomarker to differentiate thyroid follicular tumors

Glutathione - IR 797 coupled Casein Nano-Trojan for augmenting the therapeutic efficacy of camptothecin in highly invasive triple negative breast cancer

Contact Info

Product

Resources

About